SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Momenta Pharmaceuticals Inc.
An SI Board Since March 2004
Posts SubjectMarks Bans Symbol
3027 64 0 MNTA
Emcee:  michael_f_murphy Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1602Table of largest shareholders: siliconinvestor.comDewDiligence_on_SI-2/14/2008
1601The Orbimed sale is old news: sec.govDewDiligence_on_SI-2/14/2008
1600Orbimed dumped all 3.3M shares, Davidson Kempner 2.0M and Sectoral 1.6M. So farIRWIN JAMES FRANKEL-2/14/2008
1599Looks like Ridgeback was in for 1,764,826 as of 9/30 so seems flat. ijIRWIN JAMES FRANKEL-2/14/2008
1598Ridgeback Capital just filed with a 4.8% stake (as of 12/31/07). More 13G’s are DewDiligence_on_SI-2/14/2008
1597<i>Stable angina and ACS have evidently been flip-flopped: the latter was DewDiligence_on_SI-2/14/2008
1596Nice to see Palo Alto increase in holding by over 600K to 3.1M. I met them at tIRWIN JAMES FRANKEL-2/14/2008
1595The most interesting part of the CC to me was the discussion of the immunogeniciIRWIN JAMES FRANKEL-2/14/2008
1594Momenta Pharmaceuticals Reports Financial Results for the Fourth Quarter and Yeamopgcw-2/14/2008
1593$8.14 – a post-non-approvable-letter high for the share price. It looks like notDewDiligence_on_SI-2/13/2008
1592Your advanced age is making you unduly cynical :-)DewDiligence_on_SI-2/13/2008
1591>>Craig Wheeler does not think new clinical trials Yes, he is "optimIRWIN JAMES FRANKEL-2/13/2008
1590Update from BioCEO webcast: Craig Wheeler does not think new clinical trials wilDewDiligence_on_SI-2/13/2008
1589<u>Annualized</u> 4Q07 Lovenox sales by region (as reported by SNY):DewDiligence_on_SI-2/12/2008
1588Baxter Halts Heparin Production Amid Reports of Allergic Reactions By JON KAMP rkrw-2/11/2008
1587Venous Thromboembolism Is a Big, Big Problem: siliconinvestor.comDewDiligence_on_SI-1/31/2008
1586SNY’s Idraparinux fails in phase-3 AF trial: siliconinvestor.comDewDiligence_on_SI-1/26/2008
1585Hopefully more than just nvs bid for M118. And I can name a lot of biotechs nvrkrw-1/25/2008
1584>>why would nvs want to buy out mnta now? Two reasons, as I see it: - M1IRWIN JAMES FRANKEL-1/25/2008
1583<i>I think the mnta generic side is probably better off in a big pharma liDewDiligence_on_SI-1/25/2008
1582All hypothetically speaking, why would nvs want to buy out mnta now? Why would mrkrw-1/25/2008
1581oso, >>what is a good entry point? I don't know - I am under water. IRWIN JAMES FRANKEL-1/25/2008
1580>>I'd prefer they split into 2 companies, they can have a generic sideIRWIN JAMES FRANKEL-1/25/2008
1579I guess we can agree to disagree. Without a defined path which gives mnta a distrkrw-1/25/2008
1578<i>mnta only has so much bandwidth... mnta has 2 HR generic shots in lovenDewDiligence_on_SI-1/25/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News